Topical corticosteroid induced ulcerated striae

Shyam B. Verma, Bhushan Madke

Nirvan Skin Clinic, Makarpura, Vadodara, India
Datta Meghe Institute of Medical Sciences (Deemed University), Jawaharlal Nehru Medical College, Sawangi Meghe, Wardha, India

Received 15 June 2020; accepted 28 July 2020
Available online 18 November 2020

Abstract We report four cases of ulcerated striae following misuse of fixed dose combinations creams containing clobetasol propionate with antifungal and antibacterial agents. © 2020 Sociedade Brasileira de Dermatologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Case report

The authors report four cases of ulcerated striae following misuse of fixed-dose combinations (FDC) creams containing clobetasol propionate with antifungal and antibacterial agents. The present cases were overweight, between 27 – 40 years of age, and exhibited wide striae with secondary ulcerations. Three patients developed them after applying the implicated FDC creams for four months, five weeks, and five months, respectively (Figs. 1 A – B, 2A). The fourth patient (Fig. 2B) had preexisting striae following two pregnancies, many of which increased in size and ulcerated during the period of FDC application. Most ulcers were oval, some showing overhanging borders, whereas large ulcers frequently adopted the pattern of striae (Figs. 2 A – B). All ulcers were painful and were restricted to the striae. There was evidence of steroid-modified tinea corporis and history of erratic intake of oral antifungal drugs in all patients. Routine investigations were normal, including morning and evening serum cortisol levels. No biopsies were performed in view of the obvious clinical diagnosis and the possibility of delayed healing of TCS treated striae.

Discussion

The literature on ulcerated striae (US) is scarce, and the majority of case reports implicate bevacuzimab, an anti-VEGF drug, used with high dose systemic corticosteroids, in the treatment of invasive brain tumors such glioblastomas.1,2 Use of potent systemic or topical corticosteroids alone have also been implicated occasionally.3
Though not very common, the authors believe that the onset of US as a side effect of potent and super-potent topical steroids is underreported. Such creams are most frequently available as FDC, even over the counter, and are extensively misused in the treatment of superficial fungal infections in South Asia, Africa, and in many developing countries.

The authors cite some old reports for their specific clinical relevance in the present cases. Association of striae with steroid containing FDCs (triamcinolone, neomycin, gramicidin, or nystatin) dates back to 1963. Their predilection for warm, moist places prone to friction is known. They have been observed to occur as early as three weeks of application of TCS. Steroid-induced striae are wider than common SD. Some preexistent striae are known to enlarge upon application of TCS and new striae are observed to appear even after discontinuation of the cream.

Histopathological changes in striae include epidermal atrophy, loss of rete ridges, increased vascularity in striae rubra, less vascularity in striae alba, and dermal changes in extracellular matrix and fibrillary component of collagen and elastic. However, the pathologic steps underlying ulceration in striae have not been elucidated. Interestingly, steroids are known to have anti-VEGF properties, similarly to bevacizumab. While twelve cases of bevacizumab in combination with systemic steroids are reported in the English literature, both drugs individually can cause ulceration. The authors hypothesize that long-term application of a potent topical steroid such as clobetasol may lead to slow ischemia, on account of its vasoconstrictive and anti-VEGF properties, leading to ulceration. The well-documented features of profound epidermal atrophy, high degree of vascularity, limited elasticity, and reduced tensile strength of steroid induced striae reinforce this hypothesis.

In conclusion, the authors presented four cases of patients with *Tinea corporis* and US induced by FDCs containing clobetasol propionate, which are widely misused in India. The authors believe this is an underreported side effect of the FDCs that are fueling the epidemic-like situation of *Tinea corporis* in India. Drug policy makers need
to regulate permissions to manufacture and sell such hazardous and often irrational creams. It is also time for agencies such as the World Health Organization to look into this menace. Finally, the mechanism of ulceration of steroid induced striae needs to be further studied and elucidated.

Financial support

None declared.

Authors’ contributions

Shyam B. Verma: Approval of the final version of the manuscript; preparation and writing of the manuscript; manuscript critical review.

Bhushan Madke: Preparation and writing of the manuscript; critical literature review; manuscript critical review.

Conflicts of interest

None declared.

References

1. Pilitsi E, Wang S, Braniecki M, Tsoukas MM. Ulceration of steroid-induced striae distensae in a patient with a rare brain tumor on bevacizumab. Clin Oncol. 2019;4:1619.
2. Farber SA, Samimi S, Rosenbach M. Ulcerations within striae distensae associated with bevacizumab therapy. J Am Acad Dermatol. 2015;72:e33–5.
3. Stroud JD, van Dersarl JV. Striae. Arch Dermatol. 1971;103:103–4.
4. Verma S, Madhu R. The great Indian epidemic of superficial dermatophytosis: an appraisal. Indian J Dermatol. 2017;62:227–36.
5. Adam JE, Craig G. Striae and their relation to topical steroid therapy. Can Med Assoc J. 1965;92:289–91.
6. Epstein NN, Epstein WL, Epstein JH. Atrophic striae in patients with inguinal intertrigo. Arch Derm. 1963;87:450–7.
7. Oakley AM, Patel BC. Stretch Marks (Striae). Treasure Island (FL): StatPearls; 2020.
8. Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006;54:1–15, quiz 16–18.
9. Nauck M, Karakiulakis G, Perruchoud AP, Papakonstantinou E, Roth M. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol. 1998;341:309–15.
10. Murayama N, Koike Y, Ikehara S, Okubo Y, Tomimura S, Utani A. Is bevacizumab a culprit of intractable skin ulcers? J Dermatol. 2016;43:972–9.